ANTIMICROBIAL RESISTANCE –RESEARCH AND DEVELOPMENTDr Jenny FirmanPrincipal Medical Adviser, Office of Health ProtectionAustralian Government Department of Health
Australia’s First National AMR Strategy 2015-2019
• Objective Five: Agree a national research agenda and promote investment in the discovery and development of new products and approaches to prevent, detect and contain antimicrobial resistance
1
NHMRC Funded CREs – AMR Category Name Ends
University of Queensland
REdefining antimicrobial use to reDUceresistanCE (REDUCE). 2019
University of Melbourne
A National Centre for Antimicrobial Stewardship: Using a One Health Approach
2019
Bond UniversityMinimising Antibiotic Resistance for Acute Respiratory Infections (CREMARA) 2017
Queensland University of Technology
Reducing Healthcare Associated Infections (CRE-RHAI) 2017
11 July, 2017 *Source – NHRMC Research Funding 2014-2016, publicly available dataset 2
11 July, 2017 3
CREMARA REDUCE
NCAS RHAI
Delayed prescribing
Development of guidelines
Diagnostic tests and biomarkers
Cost effectiveness
studies
Modelling of novel
antimicrobial dosages
Optimisation of antibiotic therapy
Shared decision making and
patient decision aids
One Health AMS
Antimicrobial stewardship
Antimicrobial prevalence
studies
Modelling transmission
dynamics
Effective IPC interventions
and policy
Combined research themes
AMR RESEARCH
4
Medical Research Future Fund
• The Medical Research Future Fund (MRFF) supports health and medical research and innovation.
• The MRFF Strategy has a focus on the entire research system – from public health to laboratory-based research, through to health systems research and the translation of findings into health system outcomes and/or commercial products.
6
Medical Research Future Fund - AMR
7
International +++++
8
National AMR Strategy – Research needs
• Novel therapeutics, including antimicrobials, adjunct treatments, combination therapies and vaccines
• Developing rapid and point-of-care diagnostic technologies • Intervention strategies to prevent the development and
transfer of resistance across species and settings • Best-practice in antimicrobial stewardship and infection
prevention and control; and• Evidence-based key messaging to promote behaviour
change to support improved prescribing practice and the use of antimicrobials.
9
Key knowledge gaps - ASTAG
• Behavioural drivers of antimicrobial usage and effective approaches to support appropriate use across the antimicrobial supply chain.
• Economic cost burden of AMR in Australia ( human and animal).
• Targets for antimicrobial usage and prevalence rates of resistant organisms to measure impact and drive behaviour change.
• Develop point of care testing for better diagnosis and therapy
• Development of new products including new vaccines, repurposing old antibiotics
10
Next Steps
11
• AMR website will provide greater visibility to the range of AMR related research projects that are currently in progress.
• Identify how we can address research questions in partnership
12
QUESTIONS?